PREDICTIVE STATISTICS AND ARTIFICIAL-INTELLIGENCE IN THE TITUTES-DRUG-DISCOVERY-PROGRAM-FOR-CANCER-AND-AIDS

Citation
Jn. Weinstein et al., PREDICTIVE STATISTICS AND ARTIFICIAL-INTELLIGENCE IN THE TITUTES-DRUG-DISCOVERY-PROGRAM-FOR-CANCER-AND-AIDS, Stem cells, 12(1), 1994, pp. 13-22
Citations number
20
Categorie Soggetti
Cytology & Histology","Biothechnology & Applied Migrobiology
Journal title
ISSN journal
10665099
Volume
12
Issue
1
Year of publication
1994
Pages
13 - 22
Database
ISI
SICI code
1066-5099(1994)12:1<13:PSAAIT>2.0.ZU;2-F
Abstract
The National Cancer Institute's drug discovery program screens more th an 20,000 chemical compounds and natural products a year for activity against a panel of 60 tumor cell lines in vitro. The result is an info rmation-rich database of patterns that form the basis for what we term an ''information-intensive'' approach to the process of drug discover y. The first step was a demonstration, both by statistical methods (in cluding the program COMPARE) and by neural networks, that patterns of activity in the screen can be used to predict a compound's mechanism o f action. Given this finding, the overall plan has been to develop thr ee large matrices of information: the first (designated A) gives the p attern of activity for each compound tested against each cell line in the screen; the second (S) encodes any of a number of types of 2-D or 3-D structural motifs for each compound; the third (T) indicates each cell's expression of molecular targets (e.g., from 2-dimensional prote in gel electrophoresis). Construction and updating of these matrices i s an ongoing process. The matrices can be concatenated in various ways to test a variety of specific hypotheses about compounds screened, as well as to ''prioritize'' candidate compounds for testing. To aid in these efforts, we have developed the DISCOVERY program package, which integrates the matrix data for visual pattern recognition. The ''infor mation-intensive'' approach summarized here in some senses serves to b ridge the perceived gap between screening and structure-based drug des ign.